EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer

Woong Ki Park iD, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Jai Min Ryu, Byung Joo Chae

Cancers · 10.11.2023 · 15 (22) · 5361

DOI: 10.3390/cancers15225361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 10.11.2023. Verfasst von Woong Ki Park und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Samsung Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is a prevalent malignancy with increasing incidence, particularly in Asian countries. Classification based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status is pivotal in determining treatment. Recent advances have challenged the traditional dichotomy in HER2 classification, prompting investigation into the HER2-low subtype’s characteristics and outcomes. This retrospective study analyzed 10,186 non-metastatic hormone receptor (HR)-positive, HER2-negative breast cancer cases treated from 2008 to 2020. Data encompassed clinical, pathological, and treatment information. Oncologic outcomes included disease-free survival (DFS), overall survival (OS), and breast cancer-specific survival (BCSS). In total, 56.5% were HER2-low cases. Differences in patient characteristics were noted, with more BRCA1/2 mutations and higher mastectomy rates in the HER2-low group (p = 0.002, p < 0.001, respectively). Fewer received adjuvant chemotherapy or radiation therapy, and fewer histologic and nuclear grade 1 tumors were identified (all p < 0.001). With a median follow-up of 64 months (range: 13–174), HER2-low cases exhibited better DFS, OS, and BCSS than HER2-0 cases (p = 0.012, p = 0.013, and p = 0.013, respectively). Notably, the prognosis differed between premenopausal and postmenopausal subgroups, with BCSS benefitting premenopausal patients (p = 0.047) and DFS and OS benefitting postmenopausal patients in the HER2-low group (p = 0.004, p = 0.009, respectively). Multivariate analysis confirmed HER2 status as an independent predictor of these outcomes (p = 0.010, p = 0.008, and p = 0.014, respectively). This extensive single-center study elucidates the favorable prognosis associated with HER2-low status in HR-positive breast cancer. However, this effect differs among premenopausal and postmenopausal patients, necessitating further research into the underlying tumor biology.

Schlagwörter

Stichwörter der Autor:innen

HER2-lowbreast cancerhormone receptor statusmenopausal statusoncologic outcomes

Autor:innen und Institutionen

  • Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.

ORCID-Profile: Woong Ki Park

Förderung

  • Samsung Medical Center

Zitieren

APA

Park, W. K., Nam, S. J., Kim, S. W., Lee, J. E., Yu, J., Ryu, J. M., & Chae, B. J. (2023). The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer. Cancers, 15(22), 5361. https://doi.org/10.3390/cancers15225361

Vancouver

Park WK, Nam SJ, Kim SW, Lee JE, Yu J, Ryu JM, et al. The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer. Cancers. 2023;15(22):5361. doi:10.3390/cancers15225361

BibTeX
@article{Park2023,
  author = {Park, Woong Ki and Nam, Seok Jin and Kim, Seok Won and Lee, Jeong Eon and Yu, Jonghan and Ryu, Jai Min and Chae, Byung Joo},
  title = {The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {22},
  pages = {5361},
  doi = {10.3390/cancers15225361}
}
Kostenlos starten →